Precision BioSciences, Inc. (NASDAQ:DTIL) experienced a significant stock increase of 10.55%, trading at $8.38 during Wednesday's premarket session. This surge follows the release of new clinical data from the company's PBGENE-HBV program, which demonstrated the treatment's effectiveness in eliminating cccDNA, resulting in a 10-fold reduction in cccDNA-derived transcripts. Notably, all patients with detectable pgRNA at baseline achieved pgRNA loss, highlighting the program's potential in combating chronic hepatitis B. Over the past year, the stock has appreciated by 55.01%, currently trading above its short-term moving averages. The Relative Strength Index (RSI) is at 54.88, indicating a neutral momentum. Analysts maintain a Buy rating for the stock, with an average price target of $30.00. Investors are advised to keep an eye on future developments as Precision BioSciences continues to advance its innovative therapies.